Browsing Pharmacy Research by Subject "Dapagliflozin"
Now showing items 1-4 of 4
-
Cost-effectiveness analysis of dapagliflozin in addition to standard therapy in heart failure with reduced ejection fraction: A Qatari healthcare perspective
( Hamad bin Khalifa University Press (HBKU Press) , 2022 , Article)Background: Dapagliflozin has been shown to reduce the risk of heart failure hospitalization and cardiovascular mortality in patients with heart failure with reduced ejection fraction (HFrEF). 1,2 This work aims to determine ... -
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
( Taylor & Francis , 2024 , Article)Aim: To evaluate the cost-effectiveness of dapagliflozin added to standard of care (SoC) versus SoC in heart failure with reduced ejection fraction (HFrEF) and without type 2 diabetes mellitus (T2DM) patients from the ... -
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin–angiotensin–aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID-19 study
( Springer , 2022 , Article Review)Numerous studies demonstrate parallels between CVD, type 2 diabetes mellitus (T2DM) and COVID-19 pathology, which accentuate pre-existing complications in patients infected with COVID-19 and potentially exacerbate the infection ... -
Trends of use of SGLT2 inhibitors in Qatar
( Qatar University Press , 2021 , Poster)Background: Type 2 diabetes mellitus (T2DM) represents a growing health challenge in Qatar and worldwide. T2DM is associated with a high risk of cardiovascular (CV) morbidity and mortality, and progression of renal disease. ...